Skip to main content
. Author manuscript; available in PMC: 2023 Jan 6.
Published in final edited form as: Cancer Discov. 2022 Jul 6;12(7):1782–1803. doi: 10.1158/2159-8290.CD-21-1514

Figure 7. Increased burden of AICDA associated structural genomic lesions in SETD2 mutant lymphomas.

Figure 7.

A) Chromosomal alterations from BCL2 (n=3) and Setd2/BCL2 (n=3) tumors.

B) Presence of simple and complex SV events identified using JaBba.

C) Genomic track showing translocation events from the immunoglobulin and c-myc locus. The top segment (purple) shows the rearrangement junction.

D) Circos plots showing translocations in mouse tumors.

E-F) GSEA of BCL2 Vs Setd2/BCL2 tumor RNA-seq genes against human (E) or murine (F) MYC targets.

G) c-myc gene expression from BCL2 (n=4) and Setd2/BCL2 (n=4) tumors.

H) Mutation matrix for TP53 and SETD2 mutations from all cancers and DLBCL cases identified in cBIOPORTAL. Each vertical line represents one patient, with grey lines indicating no known mutation.

I) Copy number loss or deletion genome wide in SETD2 WT or mutated/loss of heterozygosity primary DLBCL patients from the NCI cohort (34).

Values represent mean ± SEM; median for (I). P values were calculated using unpaired two-tailed t test (A, I), one-way ANOVA (G) or Fisher’s exact test (H); ns, not significant; *, p<0.05.